These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25743685)

  • 1. An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.
    Breccia M; Voso MT; Aloe Spiriti MA; Fenu S; Maurillo L; Buccisano F; Tafuri A; Alimena G
    Ann Hematol; 2015 May; 94(5):771-7. PubMed ID: 25743685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M; Alimena G
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelation therapy in MDS: what have we learnt recently?
    Schmid M
    Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
    Gattermann N; Finelli C; Della Porta M; Fenaux P; Stadler M; Guerci-Bresler A; Schmid M; Taylor K; Vassilieff D; Habr D; Marcellari A; Roubert B; Rose C
    Haematologica; 2012 Sep; 97(9):1364-71. PubMed ID: 22419577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A; Stone RM
    Leukemia; 2009 Aug; 23(8):1373. PubMed ID: 19672273
    [No Abstract]   [Full Text] [Related]  

  • 9. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.
    Guariglia R; Martorelli MC; Villani O; Pietrantuono G; Mansueto G; D'Auria F; Grieco V; Bianchino G; Lerose R; Bochicchio GB; Musto P
    Leuk Res; 2011 May; 35(5):566-70. PubMed ID: 21185078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
    Merkel DG; Nagler A
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
    Wimazal F; Nösslinger T; Baumgartner C; Sperr WR; Pfeilstöcker M; Valent P
    Eur J Clin Invest; 2009 May; 39(5):406-11. PubMed ID: 19320908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
    Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
    Goldberg SL
    Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
    Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients.
    Oliva EN; Ronco F; Marino A; Alati C; Praticò G; Nobile F
    Transfusion; 2010 Jul; 50(7):1568-70. PubMed ID: 20230535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox for managing iron overload in people with myelodysplastic syndrome.
    Meerpohl JJ; Schell LK; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007461. PubMed ID: 25348770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
    Acta Haematol; 2013; 129(2):72-7. PubMed ID: 23154600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferasirox for managing iron overload in people with myelodysplastic syndrome.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2010 Nov; (11):CD007461. PubMed ID: 21069694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S; Santini V; Musallam K; Taher A
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.